Mark A. Dickson - Concepedia

Author

Mark A. Dickson

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Dickson, M.A., M A Dickson, M Dickson, M. A. Dickson, M. Dickson, M.A. Dickson, Mark A Dickson, Mark A. Dickson, Mark Andrew Dickson, Mark Dickson

372

Publications

11.5K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University University of Michigan Columbia University Irving Medical Center Dana-Farber Cancer Institute

About

Mark A. Dickson is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	41	3.6K
2	Cell Biology	8	8	1.3K
3	Health Sciences	3	3	55
4	Allergy	1	1	66
5	Anesthesia	1	1	32

Mark A. Dickson

100

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
Human Keratinocytes That Express hTERT and Also Bypass a p16<sup>INK4a</sup>-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics Mark A. Dickson, William C. Hahn, Yasushi Ino, Molecular and Cellular Biology Retain Normal GrowthTelomerase ExpressionSkin DevelopmentDevelopmental BiologyCell Regulation	2000	1.1K
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang, Journal of Clinical Oncology	2015	1.1K
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer Alicia Latham, Preethi Srinivasan, Yelena Kemel, Journal of Clinical Oncology	2018	603
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease William Connell, Michael A. Kamm, J K Ritchie, The Lancet InflammationAutoimmune DiseaseImmunologyGastroenterologyPathology	1994	491
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma Richard D. Carvajal, Jeffrey A. Sosman, J. Fernando Quevedo, JAMA	2014	421
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i> -Amplified Well-Differentiated or Dedifferentiated Liposarcoma Mark A. Dickson, William D. Tap, Mary Louise Keohan, Journal of Clinical Oncology	2013	386
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib Mark A. Dickson, Gary K. Schwartz, Mary Louise Keohan, JAMA Oncology	2016	310
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment Sandra P. D’Angelo, Alexander N. Shoushtari, Narasimhan P. Agaram, Human Pathology Tumor BiologyCancer ImmunosurveillancePd-l1 ExpressionImmunologyImmunoediting	2014	289
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 Jarushka Naidoo, Katja Schindler, Christiane Querfeld, Cancer Immunology Research ImmunodeficienciesImmunologyPathologyDermatologyImmunotherapy	2016	277
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) Gary K. Schwartz, P. LoRusso, Mark A. Dickson, British Journal of Cancer	2011	259

Page 1